香港股市 已收市

Zymeworks Inc. (ZYME)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
10.52+0.22 (+2.14%)
收市:04:00PM EDT
10.52 0.00 (0.00%)
收市後: 04:11PM EDT

Zymeworks Inc.

108 Patriot Drive
Suite A
Middletown, DE 19709
United States
(302) 274-8744
https://www.zymeworks.com

版塊Healthcare
行業Biotechnology
全職員工272

高階主管

名稱頭銜支付行使價出生年份
Mr. Kenneth H. Galbraith C.A.CEO & Chairman of the Board1.04M1963
Dr. Christopher Astle Ph.D.Senior VP & CFO682.22k1981
Dr. Paul Moore Ph.D.Chief Scientific Officer872.67k1968
Mr. Mark HollywoodExecutive VP and Head of Technical & Manufacturing Operations1970
Mr. Daniel Dex J.D., Ph.D.Senior VP, Corporate Secretary & General Counsel
Diana PapoveSenior Manager of Corporate Communications
Dr. Lindsey Foulkes B.Sc., Ph.D.Vice President of Corporate Development
Ms. Laura O'ConnorVice President of Human Resources & DEI
Dr. Jeffrey Smith M.D.Executive VP & Chief Medical Officer
Dr. Josemund Menezes MBBSManaging Director of Early-Stage Development for Asia Pacific
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

公司管治

截至 2024年3月1日 止,Zymeworks Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中:8;董事會:9;股東權利:7;現金賠償:8。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。